Application of pulsed focused ultrasound (pFUS) to deliver engineered therapeutic exosomes for the treatment of ischemic stroke
应用脉冲聚焦超声 (pFUS) 递送工程治疗性外泌体来治疗缺血性中风
基本信息
- 批准号:10741954
- 负责人:
- 金额:$ 42.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AnimalsAntibody FormationAreaBiodistributionBiogenesisBiologicalBlood - brain barrier anatomyBrainBrain Hypoxia-IschemiaCarrier ProteinsCellsCentral Nervous SystemCerebrovascular CirculationCharacteristicsChimeric ProteinsDNAEngineeringFocused UltrasoundGoalsHeat shock proteinsHuman Anti-Mouse AntibodyImmunoelectron MicroscopyImmunohistochemistryIndium-111InjectionsInvestigationIschemiaIschemic StrokeLaboratoriesLegal patentLesionLigandsLipidsLiquid substanceMagnetic Resonance ImagingMediatingMembrane ProteinsMesenchymal Stem CellsMethodsMicrobubblesMusNeuronal HypoxiaNeuronsNucleic AcidsOutcomeOxidative StressPeptidesPermeabilityPharmaceutical PreparationsPhysiologic pulseProteinsPublishingRecoveryReperfusion TherapyReportingResearch PersonnelResolutionSiteSmall Interfering RNASpecificityStrokeStroke VolumeSurfaceTechniquesTestingTherapeuticTissue SampleToxic effectbehavioral outcomebiomaterial compatibilitybrain tissueendothelial stem cellengineered exosomesexosomeimmunogenicityimmunoreactionimprovedin vivointravenous administrationnanobubblenerve stem cellneurobehavioralneuroglobinpost strokerabies virus glycoprotein Gsingle photon emission computed tomographystem cellsstroke recoverytargeted deliverytargeted treatmenttechnology platformtherapy outcomewhite matterzeta potential
项目摘要
We have shown enhanced delivery of endothelial progenitor cell (EPC) derived naïve exosomes to the sites of
stroke using pulsed-focused ultrasound (pFUS) without causing damage to the surrounding brain tissues.
Preliminary results from the study also showed that enhanced delivery of EPC exosomes (by pFUS) caused
significantly decreased stroke volume and improved cerebral blood flow over 28 days compared to that of EPC
exosomes only treated animals. Therefore, pFUS without nanobubbles can be used as a method to enhance
the delivery of IV-administered exosomes at the site stroke.
We have developed a platform to make engineered exosomes using non-tumorous HEK293 cells that carry
and express specific cell-targeting peptides as well as therapeutic probes. The objectives of this proposal are
to develop engineered exosomes using our platform to carry neuron-specific rabies virus glycoprotein (RVG)
peptides as targeting ligands for the central nervous system and to carry a targeted therapeutic probe,
neuroglobin (Ngb), to protect neurons from hypoxic/ischemic and oxidative stress-related insults following
ischemic stroke. We hypothesize that engineered exosomes carrying both targeting RVG peptides and
therapeutic Ngb protein can be delivered to the site of ischemic stroke and the delivery of these exosomes will
be enhanced using pFUS to improve the benefits of post-stroke exosome therapy. The hypothesis will be
tested with the following specific aims:
Specific Aim 1: Investigate the characteristics of the engineered exosomes and in vivo biodistribution
of intravenously (IV) administered exosomes in stroke areas with or without pFUS.
Characteristics of the engineered exosomes will be investigated to determine the size, zeta potential, and the
presence of peptide and protein on the surface or inside the lumen using techniques as per our published
methods. Then biodistribution of exosomes carrying Ngb on the surface or in the lumen ±pFUS will be
determined using In-111-tagged respective exosomes at the sites of stroke by SPECT-CT. We will also
determine the distribution of exosomes with or without RVG peptides.
Specific Aim 2: Investigate the recovery from a stroke following delivery of engineered exosomes
carrying Ngb with or without pFUS.
Exosomes will be delivered by pFUS after 24hrs of stroke; stroke recovery will be determined using MRI, and a
battery of short- and long-term behavioral outcome tests will be performed followed by immunohistochemistry
on brain tissue samples.
我们已经显示了内皮祖细胞(EPC)来源的朴素外体的增强递送到
使用脉冲聚焦超声(PFUS)治疗中风,不会对周围脑组织造成损害。
研究的初步结果还表明,EPC外切体的增强递送(由pFUS)导致
与EPC相比,EPC在28天内显著减少了每搏量并改善了脑血流量
Exosome只治疗动物。因此,无纳米气泡的pFUS可以作为一种增强
在卒中部位注射静脉注射的外切体。
我们已经开发出一种平台,可以使用非肿瘤的HEK293细胞制造工程化的外切体
并表达特定的细胞靶向多肽和治疗性探针。这项提议的目标是
利用我们的平台开发携带神经元特异性狂犬病病毒糖蛋白(RVG)的工程化外切体
多肽作为中枢神经系统的靶向配体并携带靶向治疗探针,
脑红蛋白(NGB),保护神经元免受缺氧/缺血和氧化应激相关的损伤
缺血性中风。我们假设携带靶向RVG多肽和RVG多肽的工程外体
治疗性NGB蛋白可以被输送到缺血性中风的部位,而这些外切体的输送将
使用pFUS加强治疗,以改善卒中后外显体治疗的益处。假设将是
测试的具体目标如下:
具体目的1:研究工程化外切体的特性及体内分布
在有或没有pFUS的卒中区域静脉(IV)注射外切体。
将对工程外切体的特性进行研究,以确定其大小、Zeta电位和
根据我们发表的技术,在管腔表面或管腔内存在多肽和蛋白质
方法:研究方法。那么携带NGB的外体在表面或在管腔±pFUS中的生物分布将是
用SPECT-CT在卒中部位用In-111标记的各自外显体测定。我们还将
确定含有或不含有RVG多肽的外切体的分布。
具体目标2:研究工程外切体交付后卒中的康复情况
携带NGB,有或没有pFUS。
Exosome将在中风后24小时由pFUS提供;中风的恢复将使用MRI来确定,并且
随后将进行一系列短期和长期行为结果测试,然后是免疫组织化学
在脑组织样本上。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALI SYED ARBAB其他文献
ALI SYED ARBAB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALI SYED ARBAB', 18)}}的其他基金
Neutrophil Activation after Traumatic Brain Injury
脑外伤后中性粒细胞激活
- 批准号:
10312034 - 财政年份:2018
- 资助金额:
$ 42.35万 - 项目类别:
Understanding Mechanisms of Resistance to Anti-angiogenic Treatments
了解抗血管生成治疗的耐药机制
- 批准号:
8287748 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
In vivo detection of involvement of endogenous BM progenitor cells in glioma
体内检测神经胶质瘤中内源性 BM 祖细胞的参与
- 批准号:
8551652 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
Understanding Mechanisms of Resistance to Anti-angiogenic Treatments
了解抗血管生成治疗的耐药机制
- 批准号:
8616733 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
In vivo detection of involvement of endogenous BM progenitor cells in glioma
体内检测神经胶质瘤中内源性 BM 祖细胞的参与
- 批准号:
8811180 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
In vivo detection of involvement of endogenous BM progenitor cells in glioma
体内检测神经胶质瘤中内源性 BM 祖细胞的参与
- 批准号:
8729867 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
Understanding Mechanisms of Resistance to Anti-angiogenic Treatments
了解抗血管生成治疗的耐药机制
- 批准号:
8997986 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
In vivo detection of involvement of endogenous BM progenitor cells in glioma
体内检测神经胶质瘤中内源性 BM 祖细胞的参与
- 批准号:
8415675 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
Understanding Mechanisms of Resistance to Anti-angiogenic Treatments
了解抗血管生成治疗的耐药机制
- 批准号:
8446301 - 财政年份:2012
- 资助金额:
$ 42.35万 - 项目类别:
Stem Cells as Delivery Vehicles and Imaging Probes for Glioma Gene Therapy
干细胞作为神经胶质瘤基因治疗的递送载体和成像探针
- 批准号:
7464435 - 财政年份:2008
- 资助金额:
$ 42.35万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 42.35万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 42.35万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 42.35万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 42.35万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 42.35万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 42.35万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 42.35万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 42.35万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 42.35万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 42.35万 - 项目类别: